Advisor Group Inc. boosted its position in GlaxoSmithKline plc (NYSE:GSK) by 19.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 120,590 shares of the pharmaceutical company’s stock after buying an additional 19,391 shares during the period. Advisor Group Inc.’s holdings in GlaxoSmithKline were worth $4,277,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wealthcare Advisory Partners LLC lifted its holdings in GlaxoSmithKline by 1,982.8% in the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after acquiring an additional 3,351 shares during the period. Field & Main Bank acquired a new position in GlaxoSmithKline in the fourth quarter valued at approximately $132,000. First Dallas Securities Inc. acquired a new position in GlaxoSmithKline in the fourth quarter valued at approximately $142,000. Waldron LP acquired a new position in GlaxoSmithKline in the third quarter valued at approximately $203,000. Finally, Belpointe Asset Management LLC acquired a new position in GlaxoSmithKline in the third quarter valued at approximately $204,000. Hedge funds and other institutional investors own 10.98% of the company’s stock.
GlaxoSmithKline plc (GSK) opened at $37.65 on Tuesday. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. The firm has a market capitalization of $92,200.00, a P/E ratio of 25.61, a PEG ratio of 2.27 and a beta of 0.95. GlaxoSmithKline plc has a 52 week low of $34.52 and a 52 week high of $44.53.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be paid a dividend of $0.633 per share. This represents a $2.53 annualized dividend and a dividend yield of 6.73%. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio is presently 172.11%.
GSK has been the subject of a number of analyst reports. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Tuesday, January 2nd. UBS Group raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and boosted their price target for the company from $35.04 to $35.85 in a report on Monday, November 27th. Barclays raised GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 16th. Argus decreased their price target on GlaxoSmithKline to $40.00 and set a “buy” rating for the company in a report on Thursday, November 30th. Finally, Cowen set a $38.00 price target on GlaxoSmithKline and gave the company a “hold” rating in a report on Monday, December 11th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. GlaxoSmithKline presently has an average rating of “Hold” and an average target price of $38.77.
ILLEGAL ACTIVITY NOTICE: “Advisor Group Inc. Purchases 19,391 Shares of GlaxoSmithKline plc (GSK)” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/03/13/advisor-group-inc-purchases-19391-shares-of-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.